智飞生物：子公司重组带状疱疹ZFA01佐剂疫苗（CHO细胞）临床试验获批

Core Viewpoint - The company announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its recombinant herpes zoster vaccine ZFA01 in individuals aged 40 and above [1] Group 1 - The vaccine ZFA01 is designed to prevent herpes zoster [1] - The clinical trial will focus on a specific demographic, targeting individuals aged 40 years and older [1]